Preventive immunotherapy shows some activity in pre-cancer oral lesions
A phase II trial opens up discussions on how to define success of chemoprevention studies
A phase II trial opens up discussions on how to define success of chemoprevention studies
Novel approaches including the use of a JAK-STAT inhibitor, a nomogram and assessment of eosinophil proportions are presented for improving the management of immune-related adverse events
Data from the IMbrave050 study show benefits of atezolizumab plus bevacizumab in terms of disease recurrence, but long-term data are needed
In the IND227 trial, more pronounced benefits of the immunotherapy were observed in patients with non-epithelioid histology and regardless of PD-L1 status
Promising data are reported for tumours with dMMR, MSI-H and rare POLE alterations, reinforcing the role of molecular testing for tissue-agnostic treatment
Results from the BEATcc study strongly support the use of first-line combination therapy for R/M CC in all patients
The TROP2-directed ADC improved PFS with reduced toxicity compared with chemotherapy in the TROPION-Lung01 trial, but results are not practice-changing
Positive outcomes in advanced or metastatic disease reported from EV-302/KEYNOTE-A39 and CheckMate 901 indicate an alternative to first-line chemotherapy for the first time
In the NICHE-3 study, all patients achieved a pathological response
Negative trials presented at the ESMO Congress 2023 suggest that a new treatment strategy may be required for patients with metastatic disease
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.